INTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Mar. 2024, Inhibitor Therapeutics paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Inhibitor Therapeutics spent $0.00 Mil on financial activities for the three months ended in Mar. 2024.
The historical data trend for Inhibitor Therapeutics's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibitor Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Flow from Financing | Get a 7-Day Free Trial | 2.40 | 0.10 | 0.18 | 0.18 | -0.41 |
Inhibitor Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Flow from Financing | Get a 7-Day Free Trial | -0.41 | - | - | - | - |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Inhibitor Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing | (A: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0 | + | 0 | + | -0.411 | + | 0 | + | 0 | + | 0 |
= | -0.41 |
Inhibitor Therapeutics's Cash from Financing for the quarter that ended in Mar. 2024 is:
Cash Flow from Financing | (Q: Mar. 2024 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0 | + | 0 | + | 0 | + | 0 | + | 0 | + | 0 |
= | 0.00 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibitor Therapeutics (OTCPK:INTI) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Inhibitor Therapeutics's issuance of stock for the three months ended in Mar. 2024 was $0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Inhibitor Therapeutics's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Inhibitor Therapeutics's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Inhibitor Therapeutics received $0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Inhibitor Therapeutics's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Inhibitor Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Inhibitor Therapeutics's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Inhibitor Therapeutics received $0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Inhibitor Therapeutics's other financing for the three months ended in Mar. 2024 was $0.00 Mil. Inhibitor Therapeutics received $0.00 Mil on other financial activities.
Thank you for viewing the detailed overview of Inhibitor Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Black Robe Capital Llc | 10 percent owner | 900 WEST PLATT STREET SUITE 200, TAMPA FL 33606 |
Ronald E Osman Irrevocable Trust Iii | 10 percent owner | 1602 WEST KIMMEL, P.O. BOX 939, MARION IL 62959 |
Ronald E Osman | director, 10 percent owner | 1602 KIMMEL STREET, MARION IL 62959 |
Donovan James Joseph Iii | 10 percent owner | C/O TPB 2012 LLC 12412 POWERSCOURT DR, SUITE 35, SAINT LOUIS MO 63131 |
Tpb 2012 Llc | 10 percent owner | 12412 POWERSCOURT DRIVE SUITE 35, SAINT LOUIS MO 63131 |
Michelle Yanez | director | 449 S. 12TH STREET UNIT 1705, TAMPA FL 33602 |
Niraj Vasisht | director | C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE., SUITE 225, RALEIGH NC 27612 |
James A Mcnulty | 10 percent owner, officer: See Remarks | C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146 |
Mayne Pharma International Pty Ltd | 10 percent owner | 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106 |
Mayne Pharma Ventures Pty Ltd | 10 percent owner | 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106 |
Mayne Pharma Group Ltd | 10 percent owner | 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106 |
Garrison J. Hasara | officer: CFO and Treasurer | 324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
Debra Peattie | director | 4830 W. KENNEDY BLVD., SUITE 600, TAMPA FL 33609 |
Robert Daniel Martin | director | C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
E. Brendan Magrab | director, officer: Chairman of the Board | C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
From GuruFocus
By PRNewswire • 12-13-2023
By PRNewswire • 12-19-2023
By PRNewswire PRNewswire • 10-31-2019
By PRNewswire PRNewswire • 01-22-2020
By PRNewswire PRNewswire • 08-20-2019
By PRNewswire PRNewswire • 05-06-2019
By ACCESSWIRE AccessWire • 04-12-2019
By PRNewswire PRNewswire • 11-25-2019
By PRNewswire PRNewswire • 03-07-2019
By PRNewswire PRNewswire • 04-15-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.